According to the EMA's February 2025 revision, LER studies continue to be required for MAAs involving products with formulations prone to endotoxin masking (particularly those containing surfactants and chelators). If LER is detected, the applicant should propose adequate mitigation strategies through method optimization, and finished product specifications should be set as low as reasonably achievable based on manufacturing capability. Notably, the EMA has recognized TR 82 as a relevant standard for designing LER studies while also suggesting scope expansion to include vaccines and cell and gene therapies (CGT).
[Characterize Product & Packaging] ➔ Define Tg, freezing kinetics, and CCI limits. ▼ [Select & Qualify Equipment] ➔ Conduct extreme-low temperature mapping and hold studies. ▼ [Establish Operational Controls] ➔ Implement CMS, TOE limits, and safety infrastructure. ▼ [Validate Logistics & Lifecycles] ➔ Create robust disaster recovery and transfer protocols.
Recommends using Reference Standard Endotoxin (RSE) or Control Standard Endotoxin (CSE) for initial assessments. pda technical report 82
Low Endotoxin Recovery (LER) is a time- and temperature-dependent phenomenon where a known amount of bacterial endotoxin becomes undetectable over time when spiked into an undiluted drug product. First reported publicly by Chen and Vinther in 2013, LER specifically affects biologics and monoclonal antibodies. The Criteria for LER
PDA Technical Report 82, titled "Measurement of Extractables and Leachables in Pharmaceutical Products," provides guidance on the measurement of extractables and leachables in pharmaceutical products, including the determination of solid content. According to the EMA's February 2025 revision, LER
For products confirmed to exhibit LER, TR 82 outlines several mitigation pathways:
By following these recommendations, organizations can ensure compliance with regulatory requirements, contribute to patient safety, and maintain industry best practices in sterile compounding. [Characterize Product & Packaging] ➔ Define Tg, freezing
Unlike traditional assay interference, which can usually be overridden by simple sample dilution, LER represents a true "masking" of the endotoxin. The endotoxin particles are physically altered or hidden by components within the drug formulation itself, rendering them invisible to traditional Limulus Amebocyte Lysate (LAL) assays. The Molecular Mechanism of LER
The revised TR 82 will likely address:
While the report does not claim to be a "cookbook," it provides an essential framework for developing scientifically sound LER hold-time studies and has been recognized by major health authorities—including the FDA and EMA—as a relevant standard. Since its publication in 2019, industry experience has validated many of its recommendations while also identifying areas requiring revision, leading to the current update effort that will ensure PDA TR 82 continues to serve as an indispensable resource for years to come.
Perhaps most importantly, TR 82 discusses methods to "unmask" endotoxins, such as using specific sample treatments or alternative detection methods like Recombinant Factor C (rFC). Why It Matters for Your Facility
